Preclinical data for a biotech valued at $300mm ? We're going to need better data than that 15 years into this game.
Interesting. Thanks, docihi. It's refreshing to see actual information posted.jn
The study seems to indicate that GDC-0449 had as much effect on one of the ligand-driven models as it did on the mutational model.Isn't that a very positive result which runs contrary to the P2 failures that CRIS has been through? I'd kind of written off the possibility of success vs. ligand-driven tumors. good luck -ace
clinical research:"CONCLUSIONS: These results suggest that even small reductions in vismodegib exposure can lead to large changes in antitumor activity and will help guide proper dose selection for vismodegib in the clinic"